Marksans Pharma
Drug Manufacturers - General · MARKSANS
Mid CapHealthcareHigh Growth
Mark Saldanha
Chairman & Managing Director · Pragmatic
Company DNA
Founder-Centric
About
Marksans Pharma is a Mid Cap company in the Healthcare sector, listed on NSE as MARKSANS. With a market cap of ₹8K Cr and revenue of ₹3K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Strong influence of Mark Saldanha on corporate strategy and rapid international market expansion. Its strategic mandate: To sustain rapid growth and improve margins, the company needs to pivot from generic formulations toward higher-value complex product development.
FAQ
What kind of company is Marksans Pharma?
Marksans Pharma is a Mid Cap Healthcare company (MARKSANS) in the High Growth phase with a market cap of ₹8K Cr. It is classified as Founder-Centric in culture.
What is Marksans Pharma's culture and work environment like?
Marksans Pharma has a Founder-Centric culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Strong influence of Mark Saldanha on corporate strategy and rapid international market expansion.
Who leads Marksans Pharma?
Marksans Pharma is led by Mark Saldanha (Chairman & Managing Director), a Pragmatic leader with 30 years of experience.
What are Marksans Pharma's financials?
Marksans Pharma reported revenue of ₹3K Cr in FY25 with a 5-year revenue CAGR of 20.9%. Operating margin: 17.4%. Market cap: ₹8K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandValue-Champion
LifecycleHigh Growth
Strong influence of Mark Saldanha on corporate strategy and rapid international market expansion.
Mandate
To sustain rapid growth and improve margins, the company needs to pivot from generic formulations toward higher-value complex product development.
To sustain rapid growth and improve margins, the company needs to pivot from generic formulations toward higher-value complex product development.
Financials
Revenue FY25₹3K Cr
PAT FY25₹381 Cr
Rev CAGR 5Y20.9%
OPM17.4%
NPM14.6%
ROE15.4%
ROCE16.5%
P/E21
Fwd P/E15.2
P/B2.8
D/E12.2
Mkt Cap₹8K Cr
Promoter44.1%
Institutional18%
Similar Culture
Could You Lead Marksans Pharma?
Take the Genome Benchmark →